皓元医药(688131.SH)：使用募集资金5000万元向子公司欧创生物增资，用于实施募投项目“欧创生物新型药物技术研发中心”

Core Viewpoint - The company, Haoyuan Pharmaceutical, has approved a capital increase of 50 million yuan to its subsidiary, Ouchuang Biotechnology, for the implementation of a new drug technology research and development center project [1] Group 1 - The fourth meeting of the Audit Committee and the fourteenth meeting of the Board of Directors were held on November 19, 2025 [1] - The decision to use part of the raised funds for the capital increase was made during these meetings [1] - The funds will specifically support the "New Drug Technology R&D Center" project [1]